Your browser doesn't support javascript.
loading
Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
López-Jaramillo, Patricio; González-Gómez, Silvia; Zarate-Bernal, Diego; Serrano, Andrés; Atuesta, Leonor; Clausen, Christian; Castro-Valencia, Claudia; Camacho-Lopez, Paul; Otero, Johanna.
Afiliação
  • López-Jaramillo P; Facultad de Ciencias de la Salud, Universidad de Santander (UDES), Bucaramanga, Colombia Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Quito, Ecuador.
  • González-Gómez S; Research Institute, Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia.
  • Zarate-Bernal D; Research Institute, Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia.
  • Serrano A; Research Institute, Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia.
  • Atuesta L; Research Institute, Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia.
  • Clausen C; Research Institute, Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia.
  • Castro-Valencia C; Research Institute, Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia Medical School, Universidad Libre, Cali, Colombia.
  • Camacho-Lopez P; Research Institute, Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia.
  • Otero J; Research Institute, Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia.
Ther Adv Cardiovasc Dis ; 12(6): 169-174, 2018 Jun.
Article em En | MEDLINE | ID: mdl-29546816
ABSTRACT
The simplification of fixed dose medications by using a single 'polypill' is an attractive strategy to improve adherence to medications which has shown benefit to cardiovascular risk factor control and cardiovascular disease prevention or delay in the progression of these diseases. We review the evidence obtained from a series of clinical trials demonstrating an improvement in adherence to the polypill compared to the use of each compound separately, and found similar or better control of the classical cardiovascular risk factors and a similar safety profile. These results suggest that the use of the polypill could have a beneficial impact in cardiovascular morbidity and mortality. Furthermore, the polypill has the potential to improve cost effectiveness and is simple to use. However, before recommending the implementation of the polypill in programs aimed at primary and secondary cardiovascular prevention, we are awaiting the results of several current clinical trials aimed at measuring the impact on the frequency of major cardiovascular outcomes, particularly in low-medium-income countries.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prevenção Primária / Inibidores da Agregação Plaquetária / Doenças Cardiovasculares / Custos de Medicamentos / Países em Desenvolvimento / Prevenção Secundária / Acessibilidade aos Serviços de Saúde / Renda / Anti-Hipertensivos / Hipolipemiantes Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prevenção Primária / Inibidores da Agregação Plaquetária / Doenças Cardiovasculares / Custos de Medicamentos / Países em Desenvolvimento / Prevenção Secundária / Acessibilidade aos Serviços de Saúde / Renda / Anti-Hipertensivos / Hipolipemiantes Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article